Abstract
OBJECTIVES:
In this study, we evaluated the association of molecular subtypes, clinical characteristics and pathological types with the prognosis of patients with medulloblastoma.
METHODS:
We analyzed forty patients with medulloblastoma who underwent surgical resection at our center between January 2004 and June 2014. Risk factors associated with survival, disease progression and recurrence were analyzed with a univariate Cox regression analysis, and the identified significant risk factors were further analyzed by Kaplan-Meier survival curves.
RESULTS:
Factors associated with overall survival included M stage (p=0.014), calcification (p=0.012), postoperative treatment, postoperative Karnofsky Performance Scale (KPS) score (p=0.015), and molecular subtype (p=0.005 for WNT and p=0.008 for SHH). Number of symptoms (p=0.029), M stage (p<0.001), and postoperative radiotherapy (p=0.033) were associated with disease progression. Patients with the WNT or SHH subtype had better survival outcomes than patients with non-WNT/SHH subtypes. Risk factors for disease progression-free survival were symptoms >2 and ≥M1 stage without postoperative radiotherapy. The risk of recurrence increased with advanced M stage. Protective factors for recurrence included M0 stage and a combination of chemotherapy and radiotherapy.
CONCLUSION:
We identified the risk factors associated with survival, disease progression and recurrence of medulloblastoma patients. This information is helpful for understanding the prognostic factors related to medulloblastoma.
Child; Clinical Factors; Medulloblastoma; Molecular Phenotype; Overall Survival Time; Prognosis
CLINICS 2017;72(5):294-304
Retraction requested by the Editor of CLINICS in agreement with the authors
Retraction type: Redundant publication
Comments: The same article was published almost simultaneously in the journal TRANSLATIONAL NEUROSCIENCE AND CLINICS with a different title: ‘‘Factors affecting the prognosis of children with medulloblastoma: A single institution retrospective analysis of 40 cases’’ (http://www.tncjournal.com/EN/10.18679/CN11-6030/R.2017.003).
All articles submitted to CLINICS undergo strict quality control and are checked using iThenticate software before being submitted for peer review and before acceptance. The retracted article was checked on September 26, 2016, and February 24, 2017. Unfortunately, the article was published in TRANSLATIONAL NEUROSCIENCE AND CLINICS in May 2017, so there was no way of acknowledging the publication during the evaluation process. The authors submitted all required copyright transfer documents stating that the manuscript had not been submitted to any other journal.
The authors stated the following: ‘‘It was an unintentional mistake caused by carelessness. After acceptance of our article in CLINICS, we attended a seminar. TRANSLATIONAL NEUROSCIENCE AND CLINICS indexed our paper after the seminar, and we knew nothing about this at that time. We misunderstood and thought that this would not influence the publication of our paper in CLINICS as TRANSLATIONAL NEUROSCIENCE AND CLINICS is a non-SCI journal, and the paper was indexed only internally.’’
Publication Dates
-
Publication in this collection
May 2017
History
-
Received
28 Nov 2016 -
Received
30 Dec 2016 -
Accepted
24 Feb 2017
